Showing 6451-6460 of 8695 results for "".
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- Is Teen Acne a Sign of Future Financial Success?https://practicaldermatology.com/news/is-teen-acne-a-sign-of-future-financial-success/2457586/The love of books, the need for glasses and high intelligence are traits found among the top earners in many fields across the country, and now, a Ball State University researcher suggests that teen acne may also be on this list. In his study, “
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- What Happens When "Award Winning Hair Transplant Surgeons Meet"?https://practicaldermatology.com/news/what-happens-when-award-winning-hair-transplant-surgeons-meet/2457587/Boasting "true star power" with a lineup of international speakers and educational offerings in the ever-expanding field of hair transplant surgery, the 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) heads to Hollywood October 10-14.&
- FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCChttps://practicaldermatology.com/news/fda-approves-regenerons-libtayo-first-treatment-for-metastatic-or-locally-advanced-scc/2457589/Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiatio
- Research Identifies Disparities in Outpatient Dermatologic Carehttps://practicaldermatology.com/news/research-identifies-disparities-in-outpatient-dermatologic-care/2457592/The odds of a black or Hispanic patient visiting an outpatient dermatologist are about half that of a white patient with the same skin condition, according to a new study in JAMA Dermatology. Patie
- With Launch of TruSculpt ID, Cutera Defines Today's Body Contouring Patienthttps://practicaldermatology.com/news/with-launch-of-trusculpt-id-cutera-defines-todays-body-contouring-patient/2457594/A third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results were released to coincide with the availability of truSculpt iD, a non-
- XBiotech Adds Dr. Alice Gottlieb to its Scientific Advisory Boardhttps://practicaldermatology.com/news/xbiotech-adds-dr-alice-gottlieb-to-its-scientific-advisory-board/2457599/Alice Gottlieb, MD, PhD joined XBiotech Inc.'s Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical eval
- Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfoliohttps://practicaldermatology.com/news/almirall-finalizes-acquisition-of-allergan-us-medical-dermatology-portfolio/2457600/Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for appr
- FDA Clears Sebacia Microparticles for Laser-Based Acne Treatmenthttps://practicaldermatology.com/news/fda-clears-sebacia-microparticles-for-laser-based-acne-treatment/2457603/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic